Antikolinergien käyttö vanhuksilla

Lisätietoa aiheesta
Maria Nuotio


  1. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27;127-38
  2. -
  3. Moore AR, O´Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28
  4. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
  5. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-6
  6. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807
  7. Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 2005;13:324-8
  8. Donnellan CA, Fook L, McDonald P, Playfer JR. Oxybutynin and cognitive dysfunction. Br Med J 1997;315:1363-4
  9. Edwards KR, O´Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002;49:1165-6
  10. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13
  11. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beer MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003;163:2716-24
  12. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Ibt J Clin Pract Suppl 2002;127:45-63
  13. Gill SS, Mamdani M, Naglie G ym. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005;165:808-13
  14. Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognized adverse effect with donepezil. Lancet 2000;356:568
  15. Ouslander JG, Schnelle JF, Uman G ym. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995;43:610-7
  16. Ouslander JG, Maloney C, Grasela TH, Rogers L, Walawander CA. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2001;2:207-14
  17. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493-8
Käypä hoito -suositukset ovat riippumattomia, tutkimusnäyttöön perustuvia kansallisia hoitosuosituksia. Lue lisää
Linkki toiselle sivustolle